Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
Status:
Terminated
Trial end date:
2020-10-06
Target enrollment:
Participant gender:
Summary
This is a single-center, single arm, open-label phase II study evaluating the safety,
anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical
prostatectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins